Co-Diagnostics develops test for mutated COVID-19 strain in U.K.

By staff writers

December 22, 2020 -- Co-Diagnostics announced that it has developed a molecular test for mutations that have been associated with a new variant of the coronavirus that has been causing alarm.

The company said in a statement that its polymerase chain reaction (PCR) test screens for the variant under investigation (VUI) circulating in the U.K. and causing much alarm -- VUI 202012/01. The emergence of a SARS-CoV-2 strain that appears to be more easily transmitted has led to tighter lockdowns in the U.K. and global travel bans for residents.

The performance of the company's commercially available COVID-19 tests is not thought to be adversely affected by the new strain, said Co-Diagnostics, which is based in Salt Lake City.

Co-Diagnostics gets test kit manufacturing help from Promega
Molecular diagnostics company Co-Diagnostics has tapped Promega for additional manufacturing capacity for its COVID-19 test kits.
Co-Diagnostics garners EUA for COVID-19 test
Co-Diagnostics has received emergency use authorization (EUA) from the U.S. Food and Drug Administration for its Logix Smart coronavirus COVID-19 reverse...
Co-Diagnostics raises $10.2M, sells coronavirus tests
Molecular diagnostics company Co-Diagnostics is set to raise $10.2 million in a common stock offering to institutional investors. The company plans...

Copyright © 2020

Last Updated ls 12/22/2020 4:32:19 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current